Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations: A Multicenter, Prospective, Diagnostic Clinical Cohort Study

What this Trial Is About

Researchers are conducting a prospective cohort study to develop a diagnostic prediction model for pancreatic ductal adenocarcinoma (PDAC) and other pancreatic diseases. The study enrolls patients with PDAC, individuals at high risk for PDAC, patients with other pancreatic tumors or elevated CA19-9 levels, and control participants without pancreatic disease. The goal is to improve early diagnosis, especially for resectable PDAC, by combining elastase 1 detection with other clinical and imaging tests, including endoscopic ultrasonography (EUS). Participants undergo serum sample collection to measure pancreatic elastase-1 and multi-omics analyses. For patients undergoing surgery or necessary biopsy, pancreatic tissue samples are also collected. The study uses various diagnostic examinations such as clinical serological tests and imaging to evaluate and validate the diagnostic model in different participant groups, including patients with pancreatic neuroendocrine tumors, solid pseudopapillary tumors, and those with elevated CA19-9. During the study, participants will be monitored over two years to assess the diagnostic value of the model, including sensitivity, specificity, accuracy, and predictive values. Researchers will also measure the elastase 1 content and explore new biomarkers from serum and pancreatic tissues. The study includes detailed laboratory tests, imaging, and multi-omics analyses to improve diagnosis, with regular assessments to track progress and results throughout the study period.

Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations